CO7170181A2 - Nueva composición de alfentanilo para el tratamiento del dolor agudo - Google Patents

Nueva composición de alfentanilo para el tratamiento del dolor agudo

Info

Publication number
CO7170181A2
CO7170181A2 CO14239767A CO14239767A CO7170181A2 CO 7170181 A2 CO7170181 A2 CO 7170181A2 CO 14239767 A CO14239767 A CO 14239767A CO 14239767 A CO14239767 A CO 14239767A CO 7170181 A2 CO7170181 A2 CO 7170181A2
Authority
CO
Colombia
Prior art keywords
alfentanil
treatment
acid
microparticles
acute pain
Prior art date
Application number
CO14239767A
Other languages
English (en)
Inventor
Anders Pettersson
Emil Schwan
Barbro Johansson
Original Assignee
Orexo Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48577134&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7170181(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1207701.2A external-priority patent/GB201207701D0/en
Priority claimed from GBGB1221130.6A external-priority patent/GB201221130D0/en
Application filed by Orexo Ab filed Critical Orexo Ab
Publication of CO7170181A2 publication Critical patent/CO7170181A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se proporcionan composiciones farmacéuticas para el tratamiento del dolor, por ejemplo el dolor de corta duración, comprendiendo las composiciones una mezcla que comprende: (a) micropartículas de alfentanilo, o una sal farmacéuticamente aceptable del mismo, presentándose las micropartículas en las superficies de partículas vehículos más grandes; (b) una base débil soluble en agua; y (c) un compuesto que es un ácido débil, presentándose el ácido en mezcla íntima con las mícropartículas de alfentanilo o la sal del mismo. La composición puede comprender además un disgregante. El ácido es, preferentemente, ácido cítrico.
CO14239767A 2012-05-02 2014-10-29 Nueva composición de alfentanilo para el tratamiento del dolor agudo CO7170181A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1207701.2A GB201207701D0 (en) 2012-05-02 2012-05-02 New pharmaceutical composition
GBGB1221130.6A GB201221130D0 (en) 2012-11-23 2012-11-23 New pharmaceutical composition

Publications (1)

Publication Number Publication Date
CO7170181A2 true CO7170181A2 (es) 2015-01-28

Family

ID=48577134

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14239767A CO7170181A2 (es) 2012-05-02 2014-10-29 Nueva composición de alfentanilo para el tratamiento del dolor agudo

Country Status (34)

Country Link
US (4) US8815911B2 (es)
EP (2) EP2849730B1 (es)
JP (1) JP6275696B2 (es)
KR (1) KR20150005695A (es)
CN (1) CN104427978B (es)
AU (1) AU2013255640B2 (es)
BR (1) BR112014027213A8 (es)
CA (1) CA2871805A1 (es)
CL (1) CL2014002979A1 (es)
CO (1) CO7170181A2 (es)
CY (2) CY1118570T1 (es)
DK (2) DK3150199T3 (es)
EA (1) EA028110B1 (es)
ES (2) ES2694644T3 (es)
HK (1) HK1203399A1 (es)
HR (2) HRP20161634T1 (es)
HU (1) HUE031792T2 (es)
IL (1) IL235272B (es)
IN (1) IN2014MN02156A (es)
LT (2) LT3150199T (es)
ME (1) ME02644B (es)
MX (1) MX360665B (es)
NZ (1) NZ701428A (es)
PE (1) PE20142444A1 (es)
PH (1) PH12014502407B1 (es)
PL (2) PL2849730T3 (es)
PT (2) PT2849730T (es)
RS (2) RS55489B1 (es)
SG (1) SG11201407081PA (es)
SI (2) SI3150199T1 (es)
SM (1) SMT201700086B (es)
TR (1) TR201815935T4 (es)
WO (1) WO2013164620A1 (es)
ZA (1) ZA201407559B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3939569A1 (en) 2011-09-19 2022-01-19 Orexo AB New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
DK3150199T3 (en) * 2012-05-02 2018-11-12 Orexo Ab NEW ALFENTANIL COMPOSITION FOR TREATMENT OF ACUTE PAIN
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
JP7023054B2 (ja) * 2017-04-05 2022-02-21 東和薬品株式会社 レベチラセタム含有医薬組成物及びその製造方法

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5288497A (en) 1985-05-01 1994-02-22 The University Of Utah Compositions of oral dissolvable medicaments
US5785989A (en) * 1985-05-01 1998-07-28 University Utah Research Foundation Compositions and methods of manufacturing of oral dissolvable medicaments
DE19758564A1 (de) 1997-11-11 1999-08-26 Gruenenthal Gmbh Formulierung einer Kombination aus Morphin und einem alpha¶2¶-adrenergem Agonisten und deren Verwendung
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
GB9904911D0 (en) 1999-03-03 1999-04-28 Scherer Ltd R P Pharmaceutical compositions
US6264981B1 (en) 1999-10-27 2001-07-24 Anesta Corporation Oral transmucosal drug dosage using solid solution
US20020160043A1 (en) 2001-02-27 2002-10-31 Dennis Coleman Compositions and method of manufacture for oral dissolvable dosage forms
JP4850346B2 (ja) 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
EP1587514B3 (en) 2003-01-31 2011-06-22 Orexo AB A rapid-acting pharmaceutical composition
KR101170844B1 (ko) 2003-02-24 2012-08-02 파마슈티칼 프로덕션스, 인크. 경점막 약물 전달 시스템
US20050042281A1 (en) 2003-08-21 2005-02-24 Singh Nikhilesh N. Compositions for delivering therapeutic agents across the oral mucosa
US7858121B2 (en) 2003-12-31 2010-12-28 Cima Labs, Inc. Effervescent oral fentanyl dosage form and methods of administering fentanyl
US20070036853A1 (en) 2003-12-31 2007-02-15 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
EP1708686B1 (en) 2003-12-31 2011-02-16 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
NZ548215A (en) 2003-12-31 2009-08-28 Cima Labs Inc Effervescent oral opiate dosage form
FR2883179B1 (fr) 2005-03-18 2009-04-17 Ethypharm Sa Comprime enrobe
CN101151021A (zh) 2005-03-28 2008-03-26 奥瑞克索股份公司 用于疼痛治疗的新药物组合物
US20060281775A1 (en) * 2005-06-14 2006-12-14 Applied Pharmacy Services, Inc. Two-component pharmaceutical composition for the treatment of pain
US20070104763A1 (en) * 2005-11-10 2007-05-10 Navinta Llc Composition of fentanyl citrate oral solid transmucosal dosage form, excipient and binding material therefore, and methods of making
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8535714B2 (en) * 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252328B2 (en) 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
US20100233257A1 (en) 2006-06-09 2010-09-16 Ethypharm Low dose sublingual tablets of opioid analgesics and preparation process
US20070286900A1 (en) 2006-06-09 2007-12-13 Catherine Herry Low dose tablets of opioid analgesics and preparation process
WO2008011194A2 (en) * 2006-07-21 2008-01-24 Biodelivery Sciences International, Inc. Transmucosal delivery devices with enhanced uptake
DK2101740T3 (da) * 2006-12-04 2013-11-18 Orexo Ab Nye ikke-misbrugs-farmaceutiske sammensætninger omfattende opioider
EP1964564A1 (en) 2007-04-19 2008-09-03 LAB International SRL Breakthrough Pain Management
US20090048237A1 (en) 2007-08-07 2009-02-19 Acelrx Pharmaceuticals, Inc. Compositions and methods for procedural sedation and analgesia using oral transmucosal dosage forms
US20090263476A1 (en) * 2008-04-16 2009-10-22 Jobdevairakkam Christopher N Composition of Rapid Disintegrating Direct Compression Buccal Tablet
US8343978B2 (en) 2008-08-04 2013-01-01 Adds Pharmaceuticals Llc Fast onset orodispersable tablets
WO2010027770A1 (en) 2008-09-04 2010-03-11 Mallinckrodt Inc. Crystalline forms of sufentanil citrate
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
EP2429503A1 (en) 2009-05-13 2012-03-21 Protein Delivery Solutions, LLC Pharmaceutical system for trans-membrane delivery
WO2010141505A1 (en) 2009-06-01 2010-12-09 Protect Pharmaceutical Corporation Abuse-resistant delivery systems
JP2009280611A (ja) * 2009-08-26 2009-12-03 Kyukyu Yakuhin Kogyo Kk 口腔内粘膜フィルム剤
US20110091544A1 (en) 2009-10-16 2011-04-21 Acelrx Pharmaceuticals, Inc. Compositions and Methods for Mild Sedation, Anxiolysis and Analgesia in the Procedural Setting
WO2011057199A1 (en) 2009-11-06 2011-05-12 Adenios, Inc. Compositions for treating cns disorders
US20110150989A1 (en) 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
DK3150199T3 (en) * 2012-05-02 2018-11-12 Orexo Ab NEW ALFENTANIL COMPOSITION FOR TREATMENT OF ACUTE PAIN

Also Published As

Publication number Publication date
PL2849730T3 (pl) 2017-05-31
US20170071927A1 (en) 2017-03-16
HK1203399A1 (en) 2015-10-30
SG11201407081PA (en) 2014-11-27
AU2013255640B2 (en) 2017-06-15
WO2013164620A1 (en) 2013-11-07
CL2014002979A1 (es) 2014-12-05
EA201401200A1 (ru) 2015-02-27
HUE031792T2 (en) 2017-07-28
US20150133501A1 (en) 2015-05-14
CN104427978B (zh) 2017-03-01
BR112014027213A2 (pt) 2017-06-27
LT3150199T (lt) 2018-11-12
NZ701428A (en) 2016-10-28
HRP20161634T1 (hr) 2017-01-13
AU2013255640A1 (en) 2014-11-20
US9345698B2 (en) 2016-05-24
US20180214437A1 (en) 2018-08-02
DK3150199T3 (en) 2018-11-12
ES2694644T3 (es) 2018-12-26
ME02644B (me) 2017-06-20
LT2849730T (lt) 2016-12-27
IL235272B (en) 2018-10-31
RS57951B1 (sr) 2019-01-31
US9782396B2 (en) 2017-10-10
PE20142444A1 (es) 2015-01-09
PH12014502407A1 (en) 2015-01-12
PT2849730T (pt) 2017-02-15
ZA201407559B (en) 2016-05-25
RS55489B1 (sr) 2017-04-28
PT3150199T (pt) 2018-11-21
CN104427978A (zh) 2015-03-18
DK2849730T3 (en) 2017-02-13
BR112014027213A8 (pt) 2018-01-16
SMT201700086B (it) 2017-03-08
EA028110B1 (ru) 2017-10-31
SI2849730T1 (sl) 2017-02-28
MX2014013176A (es) 2015-01-19
CY1120820T1 (el) 2019-12-11
EP2849730A1 (en) 2015-03-25
US20140005223A1 (en) 2014-01-02
CA2871805A1 (en) 2013-11-07
KR20150005695A (ko) 2015-01-14
HRP20181761T1 (hr) 2018-12-28
JP2015515974A (ja) 2015-06-04
TR201815935T4 (tr) 2018-11-21
US8815911B2 (en) 2014-08-26
JP6275696B2 (ja) 2018-02-14
CY1118570T1 (el) 2017-07-12
MX360665B (es) 2018-11-13
EP3150199A1 (en) 2017-04-05
PH12014502407B1 (en) 2015-01-12
IN2014MN02156A (es) 2015-08-28
SI3150199T1 (sl) 2018-12-31
EP2849730B1 (en) 2016-11-09
PL3150199T3 (pl) 2019-03-29
ES2614757T3 (es) 2017-06-01
EP3150199B1 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
CO6680698A2 (es) Formulación de premezcla de dexmedetomidina
BR112016001678A2 (pt) Composição, método de fabricação de um comprimido, comprimido, forma de dosagem unitária, artigo de fabricação, e, uso de uma composição, de um comprimido ou de uma forma de dosagem unitária
GT201500053A (es) Composicion farmaceutica recubierta que contiene regorafenib
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
EA201591752A1 (ru) Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы
AR097619A1 (es) Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris
CO7170181A2 (es) Nueva composición de alfentanilo para el tratamiento del dolor agudo
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
CL2010000524A1 (es) Uso de una composición tópica que comprende 3,75% de imiquimod y un portador farmacéuticamente aceptable para preparar un medicamento útil para tratar verrugas genitales o perianales.
CL2016002318A1 (es) Composición farmacéutica en forma de solución que comprende un portador líquido que comprende agua y entre 20% y 95% de uno o mas alcoholes y citrato de sildenafil disuelto en dicho portador líquido a una concentración de entre 7 y 125 mg/ml; métodos para obtenerla; forma de dosificación oral; forma de dosificación bucal; kits.
AR075041A1 (es) Composicion farmaceutica que contiene aleglitazar, proceso, uso.
EA201390950A1 (ru) Гомогенные фармацевтические пероральные лекарственные формы, содержащие лерканидипин и эналаприл или их фармацетически приемлемые соли совместно с органической кислотой
AR085399A1 (es) Combinacion antitumoral que comprende cabazitaxel y cisplatino
EA201190282A1 (ru) Фармацевтическая композиция, содержащая тамсулозин
NI201300124A (es) Los compuestos para el tratamiento y la prevención de la adhesión, las composiciones farmacéuticas relacionados con el compuesto y los métodos para la prevención y el tratamiento de adherencias.
CL2012002358A1 (es) Uso de una composicion farmaceutica oral que comprende: i) acido n-[8-(2-hidroxibenzoil)amino] caprilico o una sal del mismo, ii) vitamina b12 y opcionalmente iii) ácido fólico para preparar un medicamento util en el tratamiento de condicionews de deficiencia de vitamina b12.
AR108792A1 (es) Composiciones que comprenden timolol
ES2475942B1 (es) Composición farmacéutica de citrato de sildenafilo en forma de solución acuosa
UY33806A (es) ?compuestos novedosos de imidazoquinolina, composiciones que los contienen y su uso en el tratamiento de enfermedades mediadas por tlr7?
AR100153A1 (es) Medicamento
EA201201592A1 (ru) Способ получения липосомальной формы цитохрома с

Legal Events

Date Code Title Description
FA Application withdrawn